Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of TAK-648 in Healthy Japanese and T2DM Subjects
NCT02430870Phase 1Completed
- Sponsor
- Takeda
- Start
- Apr 2015
- Primary completion
- Sep 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of TAK-648 in type 2 diabetes mellitus (T2DM) (8 arms), sponsored by Takeda. Primary endpoints: Treatment-Emergent Adverse Events, Markedly Abnormal Laboratory Values and 2 more. Started Apr 2015; status: completed.
02
Drugs
TAK-648
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02430870.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02430870.